Literature DB >> 2359071

Raynaud's phenomenon in primary Sjögren's syndrome.

F N Skopouli1, A Talal, V Galanopoulou, C G Tsampoulas, A A Drosos, H M Moutsopoulos.   

Abstract

Our study describes the prevalence, clinical picture, course and sequelae of Raynaud's phenomenon in patients with primary Sjögren's syndrome. Furthermore, our study compares the clinical, serologic and immunogenetic profile of patients with Raynaud's phenomenon versus those without Raynaud's phenomenon. It seems that Raynaud's phenomenon is a common manifestation (33%) in patients with primary Sjögren's syndrome, precedes sicca manifestations in 42% of patients and follows a pleomorphic course; in some patients (14%) it disappears during the course of Sjögren's syndrome, in others (30%) the frequency of attacks decreases while in a 3rd group (56%) it remains the same. The local clinical sequelae of Raynaud's phenomenon in patients with primary Sjögren's syndrome are swollen hands and evidence of small, soft tissue calcifications on radiographs. Digital pulp ulcers, sclerodactyly or periungal telengiectases are not seen. It seems however, that patients with primary Sjögren's syndrome and Raynaud's phenomenon develop glomerulonephritis, myositis and peripheral neuropathy more often than patients without Raynaud's phenomenon. These differences however, had no statistical significance. Finally, the autoantibody profile is similar in patients with and without Raynaud's phenomenon, while patients without Raynaud's phenomenon and primary Sjögren's syndrome showed a negative but not statistically significant association with the HLA-DR4 alloantigen.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2359071

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  8 in total

Review 1.  Therapy of Sjögren's syndrome.

Authors:  N M Moutsopoulos; H M Moutsopoulos
Journal:  Springer Semin Immunopathol       Date:  2001

2.  Prevalence of Raynaud's phenomenon in a healthy Greek population.

Authors:  P V Voulgari; Y Alamanos; D Papazisi; K Christou; C Papanikolaou; A A Drosos
Journal:  Ann Rheum Dis       Date:  2000-03       Impact factor: 19.103

Review 3.  Conventional therapy of Sjogren's syndrome.

Authors:  Clio P Mavragani; Haralampos M Moutsopoulos
Journal:  Clin Rev Allergy Immunol       Date:  2007-06       Impact factor: 8.667

4.  Treating Sjögren's Syndrome: Insights for the Clinician.

Authors:  Claudio Vitali; Gianluigi Palombi; Pierluigi Cataleta
Journal:  Ther Adv Musculoskelet Dis       Date:  2010-06       Impact factor: 5.346

Review 5.  Sjögren syndrome.

Authors:  Clio P Mavragani; Haralampos M Moutsopoulos
Journal:  CMAJ       Date:  2014-02-24       Impact factor: 8.262

6.  Diagnostic performance of minor salivary gland biopsy, serological and clinical data in Sjögren's syndrome: a retrospective analysis.

Authors:  Veli Yazisiz; Ali Berkant Avci; Funda Erbasan; Evren Kiriş; Ender Terzioğlu
Journal:  Rheumatol Int       Date:  2008-09-18       Impact factor: 2.631

7.  Anti-centromere antibody exhibits specific distribution levels among anti-nuclear antibodies and may characterize a distinct subset in rheumatoid arthritis.

Authors:  Nobuo Kuramoto; Koichiro Ohmura; Katsunori Ikari; Koichiro Yano; Moritoshi Furu; Noriyuki Yamakawa; Motomu Hashimoto; Hiromu Ito; Takao Fujii; Kosaku Murakami; Ran Nakashima; Yoshitaka Imura; Naoichiro Yukawa; Hajime Yoshifuji; Atsuo Taniguchi; Shigeki Momohara; Hisashi Yamanaka; Fumihiko Matsuda; Tsuneyo Mimori; Chikashi Terao
Journal:  Sci Rep       Date:  2017-07-31       Impact factor: 4.379

8.  Clinical features and risk factors of Raynaud's phenomenon in primary Sjögren's syndrome.

Authors:  Wei Lin; Zhifei Xin; Xiaoran Ning; Yang Li; Xiuying Ren; Yashuang Su; Meilu Liu; Shaoying Guo; Liu Yang; Yixuan Liu; Fengxiao Zhang; Wen Zhang
Journal:  Clin Rheumatol       Date:  2021-04-29       Impact factor: 2.980

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.